Botox Boca Raton: What the FDA Labels and Trials Actually Show

Search for Botox Boca Raton and most of what comes back repeats numbers the source documents do not contain. This page is built the other way round: every figure below is taken from an FDA-approved label or a peer-reviewed trial, and each one links to the record it came from so you can check it yourself.

The six botulinum toxin products approved in the United States

Six botulinum toxin type A products currently hold FDA approval in the United States for cosmetic use on frown lines. They are not interchangeable, they are not dosed in comparable units, and their approval histories span more than three decades. Brazelia MedSpa’s injectable menu centres on Botox and Dysport; the remaining four appear here because understanding what separates them is the difference between an informed consultation and an uninformed one.

The newest of the six, Letybo, was approved on 29 February 2024 for the “temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.” That phrasing is worth reading closely, because some version of it governs all six products. The approved claim is temporary improvement in appearance. It is not a claim about skin health, collagen, or anything permanent.

What the labels actually say about onset and duration

This is where marketing copy and source documents diverge most often. The Botox Cosmetic label, revision 10/2024, states: “Typically, the initial doses of reconstituted BOTOX Cosmetic induce chemical denervation of the injected muscles one to two days after injection, increasing in intensity during the first week.” On duration it is equally specific: “The duration of effect of BOTOX Cosmetic for glabellar lines is approximately 3-4 months.”

The label also publishes the response curve from its pivotal trials, and that curve is more informative than any single duration figure, because it shows how response falls away rather than stopping abruptly.

Read that bottom row carefully. At four months, a quarter of treated participants still met the responder definition. At three months, just under half did. This is why “three to four months” is an average rather than an expiry date, and why two people treated on the same day with the same dose can reasonably report different experiences at week twelve.

The Dysport label, revision 9/2023, is less granular. It states that “the clinical effect of DYSPORT may last up to four months,” and reports treatment success at day 30 by baseline severity: 55% of participants with mild baseline lines, 52% with moderate, and 60% with severe. A pooled analysis of four phase III Botox trials, published in Dermatologic Surgery in 2012, put the Kaplan-Meier median duration at 120 days at maximum contraction among 621 treated participants, of whom 84.2% were day-30 responders. Several of that paper’s authors were employed by Allergan, which markets Botox — a point worth knowing when weighing the figure.

Botox versus Dysport: what the head-to-head evidence supports

Nearly every page offering Botox in South Florida takes a position on this, and almost none of them cite a trial. There are only a handful of randomised head-to-head comparisons, they are small, most are funded by one of the manufacturers, and the two that claim a duration winner disagree with each other in a way that tracks who paid for them.

The largest is a randomised, double-blind, single-centre trial of 180 participants published in Clinical, Cosmetic and Investigational Dermatology in 2013, comparing three products in the glabella at a 1:1:3 dose ratio. Its findings on Botox and Dysport were close to identical: median onset 5.29 days versus 5.32 days in women, and median duration to baseline 140.65 days versus 139.69 days — a difference of under one day. The authors reported that adding product identity to the duration model “had only a small influence (P = 0.0735),” which is not statistically significant, whereas the hypothesis that both sexes had the same duration “was rejected (P < 0.0001).” In plain terms: in this trial, being male or female mattered a great deal to how long results lasted, and the brand did not. That study was funded by Merz, which makes neither Botox nor Dysport but the third product tested.

Against it sits a 2011 split-forehead study in the Journal of Clinical and Aesthetic Dermatology that did find Dysport lasted longer at a 2.5:1 unit ratio, by roughly 16 days at complete efficacy. It enrolled 20 people, treated the frontalis rather than the glabella, and was supported by a grant from Medicis Aesthetics, then Dysport’s US distributor.

The “Dysport spreads more than Botox” claim

This one is repeated so widely that it is treated as settled, and the best available primary evidence points the other way. A double-blind randomised trial published in JAMA Dermatology in 2013 measured the anhidrotic field produced by 2 units of each product at equal labelled units and equal volume, in 18 women, at 28 days. OnabotulinumtoxinA produced a field of 1.49 cm² against abobotulinumtoxinA’s 0.86 cm² (p < 0.001). Botox diffused more, not less.

The caveat matters as much as the finding. The comparison used a 1:1 unit ratio, which is not how the products are used in practice, where conversion runs roughly 1:2.5 to 1:3. The authors concluded that diffusion is dose-dependent rather than a fixed property of either product, so a clinically equivalent Dysport dose would not necessarily produce a smaller field. The accurate statement is narrower than either marketing claim: at equal labelled units Botox diffuses more, diffusion tracks dose, and no trial we could locate measured diffusion at clinically equivalent doses.

The unit counts the labels specify

Dosing is individualised, but the labels do publish the doses studied, and those are the doses the approvals rest on. For Botox Cosmetic: 20 units in 0.5 mL for glabellar lines, 24 units in 0.6 mL for lateral canthal lines, and 40 units in 1 mL for forehead lines treated together with glabellar lines. For Dysport, the glabellar dose is “a total of 50 Units, divided in five equal aliquots of 10 Units each, intramuscularly to affected muscles.”

Both labels also set a floor on treatment interval. The Botox Cosmetic label states that “the safety and effectiveness of dosing with BOTOX Cosmetic more frequently than every 3 months have not been clinically evaluated.” The Daxxify label is more directive still, instructing that it “should be administered no more frequently than every three months for any indication.” A clinic offering top-ups at six or eight weeks as routine practice is operating outside what the labels support.

What the trials recorded, and why the treatment area matters

The side effects recorded in the cosmetic trials are mild and short-lived. Botox Cosmetic’s glabellar trials recorded eyelid ptosis in 3% of 405 treated participants against none on placebo; its forehead-line trials recorded headache in 9%, eyelid ptosis in 2% and brow ptosis in 2%. Dysport’s glabellar trials recorded nasopharyngitis in 10%, headache in 9% and eyelid ptosis in 2%. Those rates come from different trials, different decades and different placebo arms, so they are best read as sitting in the same low single-digit range rather than as evidence that one product is safer than the other.

The largest pooled picture comes from a systematic review and meta-analysis of 16 randomised placebo-controlled trials covering 42,405 participants, published in Aesthetic Plastic Surgery in 2016. It found a modest overall increase in adverse events against placebo, and the more useful finding is that the risk is not spread evenly across the face: glabellar treatment accounts for most of it, while crow’s feet treatment showed no significant overall increase. That is a planning insight more than a warning. It is the reason dose and placement are decided area by area rather than applied to the whole upper face at one setting.

Botulinum toxin is a prescription medicine, and every product approved in the United States carries a boxed warning about effects spreading beyond the injection site. That warning, your medical history and anything you are currently taking are reviewed at consultation, before any treatment is planned. It is a conversation with the clinician who will be holding the syringe, which is where the plan for your face is actually made.

Does Daxxify really last six months?

Daxxify is marketed on duration, and the claim rests on a definition rather than a disagreement about data. In the SAKURA 1 and SAKURA 2 phase III trials, 609 participants, the primary endpoint was measured at week 4, not at six months. Duration was a secondary outcome, and it produced two different numbers depending on what counts as the end of the effect. Median time until glabellar severity was no longer “none or mild” was 24.0 and 23.9 weeks, about five and a half months. Median time until severity returned to baseline was 27.7 and 26.0 weeks.

The popular six-month figure maps to the second of those, which is the more permissive definition: it describes the point at which the lines are as pronounced as they were before treatment, not the point at which the result still looks good. Observation was also capped at 36 weeks by design. And the label itself, as noted above, caps re-treatment at every three months regardless.

Botox Boca Raton: how treatment works at our practice

Botox injections in Boca Raton begin here with a consultation rather than with a syringe. New patients start with a consultation; a fee may apply where previous lab work needs review or other in-depth diagnostics are involved. Botox and Dysport Boca Raton appointments are performed by Khali Reed, CRNA, APRN, a master injector in Boca Raton who joined the practice in September 2026. Dr. Brazelia Lazzari, the practice’s founder and clinical director, is responsible for clinical direction, protocol design and oversight rather than day-to-day treatment.

Brazelia MedSpa sits near Mizner Park in downtown Boca Raton. Patients who come in for injectables often combine them with other treatments, and the practice’s skin and laser treatments and regenerative options such as PRP and PRF are planned alongside injectables rather than sold separately. For patients whose goals are metabolic rather than facial, the GLP-1 weight loss programme and the structured wellness programmes are the better starting point. A full view of what the practice offers is on the med spa services page.

Most people are in and out inside half an hour, and the injections themselves take only a few minutes. The time goes into deciding where they go. Before anything is drawn up you will be asked to frown, raise your brows and squint, because a muscle at rest tells you very little about how it actually moves, and it is that movement pattern rather than a diagram that sets the placement.

There is no downtime in the usual sense: you can drive yourself home and go back to work the same day. The aftercare is undemanding. Stay upright for a few hours, leave the treated area alone rather than rubbing or massaging it, and skip the gym, the sauna and anything that has you lying face down until the next day.

Timing matters more than most people expect. The Botox Cosmetic label puts the start of the effect at one to two days, building through the first week, and the label’s own trial recorded its highest responder rate at day 30. A treatment booked for a wedding, a shoot or a holiday therefore wants to sit two to four weeks ahead of the date rather than two days, which also leaves room for a small adjustment if one turns out to be useful.

Frequently asked questions

Sources and how this page was built

Every figure on this page was read from the source listed below, on the date given. Where a widely repeated number could not be traced to a primary record, we have said so in the text rather than repeating it. Where the evidence is contested or insufficient — as with the duration comparison between Botox and Dysport — we have described the disagreement instead of resolving it. Product labels were read at their current revision as of 26 September 2026.

This page describes what published labels and peer-reviewed trials report about botulinum toxin type A injections. It is general health information, not medical advice, and it is not a substitute for a consultation. Whether any treatment is appropriate for you is a clinical judgement that depends on your history and examination.

Why patients choose Brazelia MedSpa for injectables

Everything above is the honest version of this subject, and that is the most useful thing we can tell you about how this practice works. It would have been easier to publish a price per unit and a promise of six months. Instead this page tells you where the Botox-versus-Dysport question is genuinely unsettled, shows what the labels themselves say about how long a result lasts, and explains why the glabella and the crow’s feet are planned differently. A practice willing to say that in public is the same practice that will tell you, across the treatment chair, when something is not right for you.

Injectables at Brazelia MedSpa are performed by Khali Reed, CRNA, APRN, a master injector her patients know as the Facial Architect, in a practice under the medical direction of Dr. Herbert R. Slavin, MD. That pairing is the substance of the offer: an injector with deep facial anatomy training, working inside a clinic with physicians on the team, rather than a retail counter with a provider who visits on Thursdays.

Brazelia MedSpa has treated patients from the same address in downtown Boca Raton for 18 years, and sees patients from across South Florida, from Delray Beach and Boynton Beach to Deerfield Beach and Fort Lauderdale. In a field where med spas open and close within a season, that is its own kind of evidence. Patients rate the practice 4.5 out of 5 across 24 Google reviews.

A face is also rarely treated as just a face here. Because Brazelia MedSpa runs hormone, metabolic, skin and regenerative programmes under one roof, an injectable plan can take account of what else is going on — skin quality, weight change, hormonal shifts — instead of being sold in isolation. Where that is relevant to you it comes up at the consultation. Where it is not, nobody raises it.

New patients start with a consultation, and nothing is injected on a first visit unless you want it to be. You will hear what the label actually supports before you hear what it costs.